Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Bristol-Myers Squibb Company rose $1.30 (2.9%) to $46.48 on average volume. Throughout the day, 8,435,389 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,942,700 shares. The stock ranged in a price between $45.23-$46.72 after having opened the day at $45.56 as compared to the previous trading day's close of $45.18. Other companies within the Health Care sector that increased today were: Raptor Pharmaceutical ( RPTP), up 26.6%, Vision-Sciences Inc (DE ( VSCI), up 9.6%, Oramed Pharmaceuticals ( ORMP), up 9.3% and Cardica ( CRDC), up 8.7%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $74.7 billion and is part of the drugs industry. The company has a P/E ratio of 51.1, above the S&P 500 P/E ratio of 17.7. Shares are up 38.6% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Pingtan Marine Enterprise ( PME), down 65.0%, CombiMatrix Corporation ( CBMX), down 14.8%, Stereotaxis ( STXS), down 12.3% and NewLink Genetics ( NLNK), down 11.6% , were all laggards within the health care sector with Varian Medical Systems ( VAR) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.